General Atlantic, L.P. and a group of its affiliated investment vehicles disclosed a set of purchases in Alkami Technology, Inc. (NASDAQ: ALKT) totaling $50.6 million executed over three days in March 2026.
The transactions were reported as having been carried out at prices ranging from $17.17 to $18.58. The firm-level activity included the following purchases:
- On March 9, 2026, the entities acquired 842,266 shares at $17.35 per share for aggregate consideration of $14,613,315.
- On March 10, 2026, they purchased 1,103,749 shares at $17.56 per share, totaling $19,381,832.
- On March 11, 2026, a final reported transaction comprised 900,000 shares bought at $18.41 each for $16,569,000.
After these transactions, the combined holdings reported by the participating entities stand at 14,879,451 shares of Alkami Technology.
The filing lists the reporting owners as:
- General Atlantic, L.P.
- General Atlantic GenPar, L.P.
- General Atlantic Partners 100, L.P.
- GAP Coinvestments III, LLC
- GAP Coinvestments IV, LLC
- GAP Coinvestments V, LLC
- General Atlantic Partners (Bermuda) EU, L.P.
- General Atlantic Partners (Lux), SCSp
- General Atlantic (Lux) S.a r.l.
- General Atlantic GenPar (Lux) SCSp
At the time of the report, Alkami shares were trading at $18.57 with a market capitalization of $1.97 billion. The stock has shown recent strength, posting a 12.6% return over the prior week.
Separately, Alkami released its fourth-quarter 2025 financial results and related operational updates. The company reported an earnings-per-share (EPS) result of -$0.11, missing consensus EPS expectations of $0.14. Revenue for the period came in at $120.8 million, a figure that was 0.54% above analyst forecasts.
Operationally, Alkami signed 16 new digital banking clients in the fourth quarter, including six banks, representing an increase from the prior quarter. The company also introduced an Automated Stage Match feature within its Software Development Kit Wizard, a tool intended to simplify development workflows for financial institution customers.
Following the quarterly disclosure and guidance, several brokerages adjusted their price targets on Alkami. Needham lowered its target to $22 from $32 while maintaining a Buy rating, noting that fourth-quarter revenue was in line with expectations and that EBITDA estimates were exceeded. Citizens trimmed its target to $28 from $40 and kept a Market Outperform rating, citing disappointing guidance. Goldman Sachs reduced its target to $18 from $25 and retained a Neutral rating, pointing to Alkami’s 2026 revenue guidance being approximately $21 million below consensus estimates.
For investors seeking additional valuation context, InvestingPro subscribers are noted to have access to further analysis including Fair Value estimates and additional ProTips on ALKT.
This report consolidates the transaction details disclosed by the reporting entities and the company’s recently issued quarterly results and analyst reactions. No new forecasts or forward-looking assessments are offered here beyond the items disclosed above.